n-methanocarbathymidine

**n-Methanocarbathymidine** (N-MCT), also known as north-methanocarbathymidine or (north)-methanocarbathymidine, is a synthetic thymidine analog with potent antiviral activity against herpesviruses and orthopoxviruses[6][8]. It acts primarily by inhibiting viral DNA polymerase after being phosphorylated by viral thymidine kinase to its active triphosphate form[8]. N-MCT has demonstrated strong in vitro and preclinical efficacy against herpes simplex virus types 1 and 2 (HSV‑1/HSV‑2), Kaposi’s sarcoma-associated herpesvirus (KSHV), varicella-zoster virus (shingles), and smallpox[8][3][6]. The drug is under development for the treatment of neonatal herpes simplex infection and has received Orphan Drug Designation from the US FDA for this indication[3][5]. Its developer is N&N Pharmaceuticals.

Other names

1-((1s,2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)bicyclo(3.1.0)hex-2-yl)-5-methyl-2,4(1h,3h)-pyrimidinedione2,4(1h,3h)-pyrimidinedione, 1-(4-hydroxy-5-(hydroxymethyl)bicyclo(3.1.0)hex-2-yl)-5-methyl-, (1s-(1.alpha.,2.alpha.,4.beta.,5.alpha.))-2,4(1h,3h)-pyrimidinedione, 1–((1s,2s,4s,5r)–4-hydroxy–5–(hydroxymethyl)bicyclo(3.1.0)hex–2–yl)–5-methyl–